NEOGEN CORP (NEOG) research
NEOGEN CORP- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $13.98
- As of
NEOGEN CORP (NEOG): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-07.
As of . Source: SEC EDGAR filings for NEOG. Method and limitations.
Share the NEOG intelligence card
See NEOG live in the terminal
Track NEOG's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live NEOG terminal, freeActive signals for NEOG
- highCONSENSUS_SELL
3 tracked funds reduced NEOG this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +300% to NEOG (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 80% of NEOG (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 85% of NEOG (2026Q2)
- highINSTITUTIONAL_EXIT
D. E. Shaw & Co., Inc. cut 96% of NEOG (2026Q2)
FREE, NO ACCOUNT
Every signal on NEOG, as it fires
You are seeing 5 of 21 signals recorded on NEOG since 2026-05-31.
The five above landed across 2 days. The other 16 were recorded on 4 other days. 15 of the 21 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NEOG (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 640491106 · 2026Q2 | $1.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 640491106 · 2026Q2 | $772K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 640491106 · 2026Q2 | $382K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NEOG
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NEOG against its peers
NEOG's operating margin of -2.5% ranks in the 64th percentile of 20 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-28 and 2026-05-31.
| Metric | NEOG | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 870M USD | 303M USD | 69 | 20 |
| Gross margin | 46.9% | 64.4% | 25 | 17 |
| Operating margin | -2.5% | -13.9% | 64 | 20 |
| Net margin | -0.9% | -13.6% | 64 | 20 |
| Return on equity | -0.4% | -11.8% | 64 | 20 |
| P / E | n/a | 31.9x | n/a | 5 |
Peers (20): AXGN, BFLY, UFPT, ESTA, IART, AORT, AVNS, BBNX, ENOV, CBLL, INMD, SIBN, BIO, GMED, QDEL, SNN, SSII, KIDS, DCTH, SENS. Left out: ALMR (no annual filing), OSSUY (no annual filing), NHNKF (no annual filing), LMRI (no annual filing), BWAY (period gap). Fiscal periods ending between 2025-12-28 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (NEOG: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more NEOG signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NEOGand get the insider, 13F, options, and confluence read in one view.